Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Healthcare delivery for HIV-positive people with tuberculosis in Europe

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review


  1. Uptake of the lateral flow urine LAM test in Europe and Central Asia

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19: A Randomized Controlled Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • A K Bentzon
  • A Panteleev
  • V Mitsura
  • E Borodulina
  • A Skrahina
  • E Denisova
  • S Tetradov
  • R Podlasin
  • V Riekstina
  • Z Kancauskiene
  • D Paduto
  • A Mocroft
  • T Trofimova
  • R Miller
  • F Post
  • A Grezesczuk
  • J D Lundgren
  • M Inglot
  • D Podlekareva
  • N Bolokadze
  • O Kirk
  • TB:HIV Study Group
Vis graf over relationer

BACKGROUND: In a 2013 survey, we reported distinct discrepancies in delivery of tuberculosis (TB) and HIV services in eastern Europe (EE) vs. western Europe (WE).

OBJECTIVES: To verify the differences in TB and HIV services in EE vs. WE.

METHODS: Twenty-three sites completed a survey in 2018 (EE, 14; WE, nine; 88% response rate). Results were compared across as well as within the two regions. When possible, results were compared with the 2013 survey.

RESULTS: Delivery of healthcare was significantly less integrated in EE: provision of TB and HIV services at one site (36% in EE vs. 89% in WE; P = 0.034), and continued TB follow-up in one location (42% vs. 100%; P = 0.007). Although access to TB diagnostics, standard TB and HIV drugs was generally good, fewer sites in EE reported unlimited access to rifabutin/multi-drug-resistant TB (MDR-TB) drugs, HIV integrase inhibitors and opioid substitution therapy (OST). Compared with 2013, routine usage of GeneXpert was more common in EE in 2018 (54% vs. 92%; P = 0.073), as was access to moxifloxacin (46% vs. 91%; P = 0.033), linezolid (31% vs. 64%; P = 0.217), and bedaquiline (0% vs. 25%; P = 0.217). Integration of TB and HIV services (46% vs. 39%; P = 1.000) and provision of OST to patients with opioid dependency (54% vs. 46%; P = 0.695) remained unchanged.

CONCLUSION: Delivery of TB and HIV healthcare, including integration of TB and HIV care and access to MDR-TB drugs, still differs between WE and EE, as well as between individual EE sites.

TidsskriftHIV Medicine
Udgave nummer4
Sider (fra-til)283-293
Antal sider11
StatusUdgivet - apr. 2021

Bibliografisk note

© 2020 British HIV Association.

ID: 61388930